Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01484327
Other study ID # 2008-CAR-EL-02
Secondary ID Carvedia - 02
Status Completed
Phase
First received
Last updated
Start date January 2009
Est. completion date November 2011

Study information

Verified date November 2011
Source Elpen Pharmaceutical Co. Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Beta-blockers should be administered to all patients with heart failure stages II to IV NYHA. It should also be administered to patients with stage I after myocardial infarction. The low ejection fraction, especially after myocardial infarction is a strong indication for beta-blockers, as many studies indicate that administration of these drugs substantially reduces cardiovascular mortality. Beta-blockers reduce mortality and hospitalizations and improve the operational phase for all categories of patients with heart failure. Since beta-blockers, only carvedilol, metoprolol, and recently visoprololi nevimpololi have shown these benefits and thus, only those have to be administered. The clinical study Carvedia aims to observe and record the action of beta-blocker carvedilol on cardiac function in patients with heart failure or reduced left ventricular ejection fraction after acute myocardial infarction.


Description:

The relationship between stroke volume, which is extruded from the left ventricle gives a measure for the restrictive left ventricular function. Any patient with known cardiovascular disease should undergo assessment of left ventricular function by measuring the ejection fraction. Several studies have shown that when the ejection fraction (LVEF), which measures the heart's ability to eject blood to the aorta does not exceed 40% (natural price ^ 50%) increased dramatically in the post-infarction mortality. The ejection fraction as a reliable predictor, can be measured by ultrasonography. The reduced ejection fraction is associated with an increased risk of life-threatening arrhythmias, heart failure and death. The low ejection fraction, especially after myocardial infarction is a strong indication for beta-blockers, as many studies indicate that administration of these drugs substantially reduces cardiovascular mortality.


Recruitment information / eligibility

Status Completed
Enrollment 415
Est. completion date November 2011
Est. primary completion date November 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: 1. Patients visiting outpatient clinics. 2. Male or female patients over 18 years 3. Patients with mild heart failure and history of symptoms according to the instructions of the European Society of Cardiology (ESC) 4. Patients who entered the study have LVEF <40% in echocardiography 5. Patients with new diagnosis of heart failure 6. Patients who have left ventricular ejection fraction after acute myocardial infarction <40% 7. Patients who have been treated in hospital during the previous month before their inclusion in the study 8. Patients who have signed the consent form for recording and processing of personal data. 9. Patients who are willing to comply with the requirements of the study 10. Patients who are treated with carvedilol for at least a month before their inclusion in this Exclusion Criteria: 1. Patients under 18 years 2. Patients with unstable chronic heart failure 3. Patients with unstable hemodynamic profiles 4. Patients with heart valve disease 5. Patients with hypertrophic cardiomyopathy 6. Patients with unstable angina or active myocarditis 7. Patients with contraindications to treatment with beta-adrenergic receptors 8. Patients who have not consented to recording and processing of personal the data. 9. Women pregnant or breastfeeding 10. Patients have been treated in hospital during the preceding months before their inclusion in the study 11. Patients treated with carvedilol for less than one month

Study Design


Intervention

Drug:
Carvedilol
Minimum dosage 3.125 mg ? 2, Maximum dosage 50 mg

Locations

Country Name City State
Greece Cardiology University Clinic Alexandroupolis

Sponsors (1)

Lead Sponsor Collaborator
Elpen Pharmaceutical Co. Inc.

Country where clinical trial is conducted

Greece, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Left Ventricular Ejection Fraction LVEF(%) Change from baseline in Left Ventricular Ejection Fraction LVEF(%) at 12 months. 0 (baseline), 48 weeks (12 months)
Secondary Number of study participants with Adverse Events Safety of carvedilol administration (reported AEs) from baseline until 12 months of treatment. 0 (baseline), 24 weeks (6 months), 48 weeks (12 months)
Secondary Cardedilol dosage range Relation between carvedilol dose titration and change in LVEF 0 (baseline), 24 weeks (6 months), 48 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy